POTOMAC, Md., June 10, 2026
IGC Pharma, Inc. (NYSE American: IGC) announced that its Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer’s dementia has achieved the company’s previously announced enrollment target, with 146 patients successfully randomized at baseline. The milestone marks a significant advancement for the clinical-stage biotechnology company as it moves closer to generating topline efficacy and safety results for its lead therapeutic candidate. The CALMA study is designed as a randomized, double-blind, placebo-controlled trial aimed at evaluating the potential of IGC-AD1 to address one of the most challenging neuropsychiatric symptoms experienced by Alzheimer’s patients. The company stated that limited over-enrollment activities will continue to offset potential patient attrition and support more comprehensive modified intent-to-treat, end-of-treatment, and exploratory analyses.
CALMA Trial Targets Significant Unmet Need in Alzheimer’s Care
Agitation is among the most common and burdensome symptoms associated with Alzheimer’s dementia, often leading to increased caregiver stress, reduced patient quality of life, and higher healthcare utilization. Despite its prevalence, treatment options remain limited, creating a substantial unmet medical need. The CALMA trial is evaluating whether IGC-AD1 can provide a safe and effective therapeutic alternative for managing agitation in patients with Alzheimer’s disease. Company executives highlighted that achieving the enrollment target reflects strong engagement from investigators, study coordinators, patients, and caregivers participating across trial sites. The successful recruitment milestone positions the study for completion and enables the collection of a robust clinical dataset needed to assess the treatment’s potential benefits.
Company Advances Toward Topline Data and Clinical Evaluation
Following the completion of patient enrollment and ongoing follow-up activities, IGC Pharma plans to initiate critical next-stage clinical operations, including database management, site closeout procedures, and preparation for topline data analysis. The company expects that maintaining a strong evaluable patient population through limited over-enrollment efforts will enhance the statistical quality of the final dataset. If positive, the Phase 2 results could support further development of IGC-AD1 and potentially pave the way for larger late-stage clinical studies. The upcoming data release will be closely watched by investors and clinicians seeking new therapeutic approaches for Alzheimer’s-related behavioral symptoms.
Advertisement
IGC Pharma Expands Neurodegenerative Disease Pipeline
IGC Pharma is a clinical-stage biotechnology company focused on developing innovative therapies for Alzheimer’s disease, neurodegenerative disorders, and metabolic conditions, while integrating artificial intelligence technologies into drug discovery and clinical development. In addition to IGC-AD1, the company is advancing TGR-63, a program targeting amyloid plaque pathology associated with Alzheimer’s disease, along with additional early-stage candidates focused on tau-related neurodegeneration and metabolic dysfunction. By combining proprietary drug development capabilities with AI-driven analytics, IGC Pharma aims to improve patient selection, optimize clinical trial outcomes, and accelerate therapeutic innovation. The CALMA trial enrollment achievement represents an important milestone in the company’s strategy to bring new treatment options to patients affected by Alzheimer’s disease and related neurological disorders.
Source: IGC Pharma release
